Entry into a Material Definitive Agreement

Business Context and Reporting Period

Company: Coeptis Therapeutics Holdings, Inc. (Ticker: COEP) reporting on behalf of the transaction with Z Squared, Inc.

Date: April 25, 2025

Event: Entry into a Material Definitive Agreement (Merger Agreement) to acquire Z Squared, Inc. via a reverse merger structure. Concurrently, Coeptis will spin out its biopharmaceutical operations to existing shareholders prior to the closing.

Key Financial Metrics and Transaction Terms

Merger Consideration: Z Squared shareholders will receive a portion of Coeptis Common Stock representing the "Applicable Percentage" of Coeptis's fully-diluted shares at closing. No specific share ratio or dollar value is provided in this filing.

Asset Valuation Condition: Closing is conditioned on Z Squared having a "Company Asset Value" of not less than $660,300,000, less assumed debt and transaction expenses.

Physical Asset Condition: Z Squared must deliver at least 9,000 mining machines at closing.

Breakup/Termination Fees:

  • $5 million payable to Coeptis if terminated due to a "Company Trigger Event."
  • $5 million payable to either party if terminated due to a "Purchaser Triggering Event" or "Company Triggering Event" by the other party.

Financial Data: The filing does not provide revenue, profit, cash flow, or margin data for either entity. It does not disclose current debt levels or liquidity positions.

Material Changes and Transaction Structure

Corporate Structure Change:

  • Spin Out: Coeptis will divest its biopharmaceutical business to a new entity spun out to current Coeptis shareholders.
  • Merger: A Coeptis subsidiary (Merger Sub) will merge with Z Squared. Z Squared will survive as a wholly-owned subsidiary of Coeptis.
  • Rebranding: Coeptis will change its corporate name to a mutually agreed-upon name at closing.

Management Transition: The CEO and CFO of Z Squared will become the CEO and CFO of the combined company immediately post-closing.

Board Composition: The post-closing board will consist of five individuals, with a majority qualifying as independent directors under Nasdaq rules.

Guidance, Outlook, and Risks

Conditions to Closing:

  • Approval by shareholders of both Coeptis and Z Squared.
  • Effectiveness of the SEC Registration Statement (Form S-4).
  • Nasdaq listing approval for the new common stock.
  • Compliance with the "Broadstreet Order" by Z Squared.
  • No Material Adverse Effect (MAE) on either party since the agreement date.

Termination Rights: The agreement may be terminated by mutual consent, failure to satisfy conditions by the "Outside Date" (3 months from signing, extendable by 3 months if SEC approval is pending), or specific triggering events (e.g., uncured breaches, MAE, failure of shareholder votes).

Risks:

  • Failure to meet the $660.3 million asset value threshold or deliver 9,000 mining machines.
  • Regulatory or antitrust delays.
  • Shareholder rejection of the transaction.

Outlook: Management intends to use commercially reasonable efforts to close the transaction. No specific financial guidance for the combined entity is provided in this filing.

Investor Verification Checklist

  • Asset Valuation: Verify the methodology and third-party validation of Z Squared's $660.3 million "Company Asset Value."
  • Asset Delivery: Confirm the existence, condition, and operational status of the 9,000 mining machines required for closing.
  • Spin Out Details: Review the specific terms of the biopharmaceutical spin-out to understand the residual value of the Coeptis entity post-transaction.
  • Shareholder Approval: Monitor the upcoming special meetings for both Coeptis and Z Squared to assess voting support.
  • Regulatory Status: Check the status of the Form S-4 registration statement and any pending regulatory reviews (e.g., Broadstreet Order compliance).
  • Dilution Impact: Analyze the "Applicable Percentage" of stock to be issued to Z Squared shareholders to determine the dilution impact on existing Coeptis shareholders.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.